BWR initiates research on AVI BioPharma Inc.

0 Comments | M2 Presswire, October, 2004

M2 PRESSWIRE-29 October 2004-bellwetherreport.com: BWR initiates research on AVI BioPharma Inc(C)1994-2004 M2 COMMUNICATIONS LTD RDATE:10292004 Bellwether Report issues aggressive investor alert for AVI Biopharma Inc (Nasdaq:AVII), an emerging biopharmaceutical company and a pioneer in the development of therapeutic products based upon two platform technologies; Cancer Immunotherapy and Gene-Targeted Drugs.

The company announced today that Qing Ge, Ph.D., of the Massachusetts Institute of Technology (MIT) Center for Cancer Research, presented data characterizing the effect of AVI's NEUGENE(R) drugs when applied to the influenza virus in cell culture. Study results were presented at the American Society of Microbiology's Interscience Conference on...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)